Home / Business and Economy / Amgen vs. Iovance: Stability or Cancer Breakthrough?
Amgen vs. Iovance: Stability or Cancer Breakthrough?
24 Jun
Summary
- Amgen's 2025 revenue neared $36.7 billion with a 9.9% growth rate.
- Iovance focuses on advanced tumor-infiltrating lymphocyte cancer therapies.
- Amgen's debt-to-equity ratio was 6.3x as of December 2025.
Investors considering Amgen (NASDAQ:AMGN) and Iovance Biotherapeutics (NASDAQ:IOVA) must evaluate stability against growth potential. Amgen, a large pharmaceutical company, offers a broad drug portfolio and generated nearly $36.7 billion in revenue in FY 2025, a 9.9% increase year-over-year. This performance resulted in a net income of approximately $7.7 billion, with a net margin of 21.0%.
As of December 2025, Amgen's financial standing showed a debt-to-equity ratio of 6.3x and a current ratio of 1.1x, with free cash flow close to $8.1 billion for the year. The company's global sales are heavily reliant on three major wholesalers, which accounted for 77% of its worldwide gross revenues in 2025, presenting a concentration risk.
In contrast, Iovance Biotherapeutics is an emerging biotech firm concentrating on tumor-infiltrating lymphocyte (TIL) therapies for cancer. Its key products, Amtagvi and Proleukin, are distributed through specialized centers and distributors. Iovance utilizes its internal iCTC manufacturing facility, emphasizing control over its complex production processes and the clinical adoption of its novel oncology treatments.
